Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Mallinckrodt
Moodys
McKesson
Express Scripts

Last Updated: August 13, 2022

CLINICAL TRIALS PROFILE FOR CHOLESTYRAMINE LIGHT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Cholestyramine Light

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000461 ↗ Harvard Atherosclerosis Reversibility Project (HARP) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1986-12-01 To determine by sequential coronary arteriography whether a lipid-lowering diet with and without lipid-lowering drugs could reverse coronary artery disease in normocholesterolemic patients. Also, to test whether fish oil supplements could improve human coronary atherosclerosis. Finally, to determine the effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. At least three clinical trials were conducted.
NCT00000463 ↗ Post Coronary Artery Bypass Graft (CABG) Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1987-04-01 To determine the relative effectiveness of moderate versus more aggressive lipid lowering, and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous vein coronary bypass grafts placed 1 to 11 years previously.
NCT00000488 ↗ Lipid Research Clinics Coronary Primary Prevention Trial (CPPT) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1973-06-01 To determine whether reduction of cholesterol by drug therapy significantly lowered the atherosclerotic coronary heart disease rate in a group of hypercholesterolemic but otherwise healthy men. Total dollars spent on the CPPT from June 1973 were $142,250,000. We do not have a year-by-year breakdown.
NCT00000594 ↗ NHLBI Type II Coronary Intervention Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1971-11-01 To determine whether lowering of cholesterol with cholestyramine in a population with Type II hyperlipidemia led to a decreased rate of progression (a regression of coronary artery disease) as demonstrated by death, myocardial infarction, or progression of disease on angiography.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cholestyramine Light

Condition Name

Condition Name for Cholestyramine Light
Intervention Trials
Myocardial Ischemia 4
Cardiovascular Diseases 4
Coronary Disease 4
Heart Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cholestyramine Light
Intervention Trials
Hypercholesterolemia 5
Coronary Artery Disease 4
Hyperlipoproteinemia Type II 4
Cardiovascular Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cholestyramine Light

Trials by Country

Trials by Country for Cholestyramine Light
Location Trials
United States 18
Germany 9
Netherlands 5
Brazil 4
Mexico 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cholestyramine Light
Location Trials
North Carolina 3
Missouri 3
Ohio 2
Kentucky 2
Minnesota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cholestyramine Light

Clinical Trial Phase

Clinical Trial Phase for Cholestyramine Light
Clinical Trial Phase Trials
Phase 4 7
Phase 3 9
Phase 2/Phase 3 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cholestyramine Light
Clinical Trial Phase Trials
Completed 27
Recruiting 3
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cholestyramine Light

Sponsor Name

Sponsor Name for Cholestyramine Light
Sponsor Trials
Sanofi 6
National Heart, Lung, and Blood Institute (NHLBI) 4
Regeneron Pharmaceuticals 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cholestyramine Light
Sponsor Trials
Other 36
Industry 18
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Harvard Business School
Express Scripts
Moodys
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.